Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension

Brown, Jr RS, Collins MA, Strasser SI, Emmett A, Topp AS, Burroughs M, et al. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infect Dis Ther [Internet]. 2022;11(2):913-924. https://doi.org/10.1007/s40121-022-00599-8

Publication Type:

Journal Article

Authors:

Brown, RS Jr; Collins, MA; Strasser, SI; Emmett, A; Topp, AS; Burroughs, M; Ferreira, R; Feld, JJ

Source:

Infect Dis Ther, Volume 11, Issue 2, p.913-924 (2022)

URL:

https://doi.org/10.1007/s40121-022-00599-8

Keywords:

Glecaprevir, Hepatitis C, Pibrentasvir, portal hypertension, sustained virologic response

Cited On:

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/35174470/

Export Citation:
RIS Format
Top